Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (August 2023)
36 slides from Recce Pharmaceuticals's investor presentation, August 2023

Slide 1: Corporate Presentation
Corporate Presentation ASX:RCE | FSE:R9Q August 2023

Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this pre

Slide 3: Board and Management Structure
Board and Management Structure Dr John Prendergast – Chairman BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) US-based, current Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) Michele Dilizia – Executive Director & Chief Scientific Officer BSc (Med Sci), Grad Dip Bus (Mkting), BA (Jou

Slide 4: About Recce Pharmaceuticals Ltd
About Recce Pharmaceuticals Ltd • Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives, protected by Composition of Matter Patent • Australian clinical-stage biotech company, with a United States presence • Strong pre-clinical data package demonstrati

Slide 5: Platform Technology
Platform Technology Recce’s products will treat systemic and local infections caused by ESKAPE pathogens, other resistant organisms or when the etiology of the infection is unknown • Very broad-spectrum coverage of bacteria with no signs of resistance • Extremely rapid onset of effect – measured in

Slide 6: Strong Pipeline
Strong Pipeline Over Various Indications and Upcoming Inflection Points Asset and Indications Discovery Pre-Clinical Phase I Phase II Phase III Market Route of Administration Serious/life threatening bacterial R327 Intravenous* infections including sepsis Urinary tract infections including urosepsis

Slide 7: Sepsis – it's a big problem!
Sepsis – it’s a big problem! 2 What is Sepsis? Economic Impact Social Impact Sepsis is a life-threatening Is the most expensive Kills more people in the US inflammatory response to condition to treat in the than prostate, breast cancer infection that has spread in last 8 years5. and HIV/AIDS combine

Slide 8: Sepsis Patient Journey
Sepsis Patient Journey Patient Presents at the Hospital Early treatment with an effective antibiotic is key to improving patient outcome • 1/3 of patients present non-specific symptoms, leading to delayed treatment and high mortality rate. MENINGITIS • Mortality from sepsis increases by as much as 8

Slide 9: Urinary Tract Infections and Urosepsis
Urinary Tract Infections and Urosepsis The Infection In approximately 30% of all septic patients the • Urinary tract infection (UTI) is one of the most common infectious focus is localised in the urogenital tract infectious diseases • The most common pathogen causing UTIs is E. coli with 90% • More

Slide 10: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives
The Need for a New Class of Antibiotics: Synthetic Anti-Infectives • NO pre-formed natural superbugs. • Entirely man-made and designed with purpose. • Universal Mechanism of Action - does not succumb to resistance. • Broad Spectrum capability and maintains its activity even with repeated use. • Empo

Slide 11: Independent Study Undertaken on R327 MoA
Independent Study Undertaken on R327 MoA1 By Leading Experts in Bacterial MoA Analysis Stage 1 Stage 2 R327 arrests cell growth and R327 disrupts bacterial cellular permeabilizes cell membranes energetics, depleting ATP • Novel mechanism which targets rapid access to and shut down of bacterial energ

Slide 12: RECCE 327 Activity Against Escherichia coli
RECCE® 327 Activity Against Escherichia coli • E. coli grows fast. Eukaryotic cells healthy Without R327 R327 (3,000 ppm) and not affected. • R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells. • R327 rapidly and irreversibly shuts down

Slide 13: RECCE 327 Activity Against Staphylococcus aureus
RECCE® 327 Activity Against Staphylococcus aureus • S. aureus bacterial growth slower than E. coli, not Without R327 R327 (2,300 ppm) affecting eukaryotic cells. • R327 at 2,300 ppm shown to be highly effective against S. aureus without affecting growing, healthy eukaryotic cells. • R327 rapidly and

Slide 14: R327 Faster Acting Than Existing Antibiotics
R327 Faster Acting Than Existing Antibiotics No Prolonged Exposure Needed • R327 kills pathogenic bacteria at a faster rate. • R327 designed to work faster than all existing antibiotics, reinforced by MoA work undertaken by experts in their field. “R327 kills bacteria in conditions where other antib

Slide 15: Bactericidal Effect of RECCE 327 on ESKAPE Pathogens
Bactericidal Effect of RECCE® 327 on ESKAPE Pathogens Control Control Control Control Control Control • Average time-kill curves of R327 at various concentrations against strains of ESKAPE pathogens (tested in duplicate) • Time-kill study was performed to determine the bacterial killing effect of R3

Slide 16: Phase I Human Clinical Trial - Complete
Phase I Human Clinical Trial - Complete 120x dose amount* 6,000 mg ✓ • Study to assess IV infusion of RECCE® 327 in healthy male subjects as a single ascending dose. 80x dose amount* 4,000 mg ✓ • Randomized, double-blind, placebo-controlled, safety, tolerability and pharmacokinetics study. 60x dose

Slide 17: RECCE 327 Concentrates Safely in the Urine
RECCE® 327 Concentrates Safely in the Urine Concentration of R327 in Ratio Urine Compared to Urine/Plasma - Plasma 16x 17x 14x 9x In over 60 healthy 21x subjects 16x – R327 primary route of elimination appears to be through – Opportunities for therapeutic in array of UTIs (uncomplicated the kidney t

Slide 18: RECCE 327 - Intravenous formulation – Phase I
RECCE® 327 - Intravenous formulation – Phase I Summary of Results – All Primary Endpoints Achieved ü No serious adverse events (SAEs) or deaths were reported in this study. ü No clinically significant changes were noted in any hematology parameter(s) in any cohort during the course of the study. ü N

Slide 19: RECCE Kills Quickly in the Urine
RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Treated with RECCE® 327 in Urine 10.00 • R327 in the presence of human urine was able to have a fast (near minutes) effect against E. coli 9.00 and irreversible Viable Bacteria (log CFU/ml) 8.00 • Bacteria could not be revived post-treatment V

Slide 20: Topical RECCE 327 – Phase I/II
Topical RECCE® 327 – Phase I/II Patient examples from ongoing Burn Wound trial • Patients suffered major burn injury. • Multiple bacterial species in and surrounding wound. • Growth swabs with organisms including pathogens from the ESKAPE group of bacteria. Pre-treatment, significant Post R327 treat

Slide 21: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 0 Day 0 After 24 hours After 30 days Pre-treatment First Recce Gel Application Post Treatment Post Treatment infection Gel Applied Complete • Patient Y unresponsive to 4 x daily Cephalexin for 10 days – Infection spreading and hospi

Slide 22: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 7 Day 10 Day 14 Day 0 – Recce treatment Day 7 – Recce treatment Day 10 – Recce treatment Day 14 – Recce treatment Significant bacterial infection Initial redness and swelling No signs of infection, no signs of pus Wound impr

Slide 23: Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial
Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial Clinical Trial Overview Outpatient Nurses Appointed • Human Research Ethics approval received • Patients enrolled in Phase I/II now supported • Phase I/II to assess safety and efficacy of R327 by in-home (out-patient) nurses trained in on mild skin

Slide 24: Patents
Patents Four families across all major markets Patent Patent Patent Expiry Expiry Expiry Filed Family 1 Family 2 Family 3 Australia ✓ 2028 ✓ 2037 ✓ 2037 USA ✓ 2029 ✓ 2037 ✓ 2037 Europe ✓ 2028 ✓ 2037 ✓ 2037 Germany ✓ 2028 ✓ 2037 ✓ 2037 Spain ✓ 2028 ✓ 2037 ✓ 2037 France ✓ 2029 ✓ 2037 ✓ 2037 UK ✓ 2028

Slide 25: Pre-Clinical Study Outlook
Pre-Clinical Study Outlook • Recce’s new Anti-Infective Research (AIR) Unit Dr Philip Sutton’s Pre-Clinical Update – Located within Murdoch Children’s Research Institute, one of the top three children’s research institutes worldwide – Fit-for-purpose laboratory space with a dedicated Murdoch Childre

Slide 26: Manufacturing & Scalability
Manufacturing & Scalability Manufacturing facility in Sydney’s Macquarie Park • Raw materials plentiful and cheap – few $/Kg • No expensive waste – 99.9% product yield • Automated manufacture process taking approx. 1 hour, 500 doses produced per automated run • This in-house pilot facility provides

Slide 27: Multiple Upcoming Clinical Milestones
Multiple Upcoming Clinical Milestones Topical R327 Burn Wounds Key inflection points Burn Wounds H1: Initiate Phase I/II Q4 23: Readout of Burn Wound Infection Phase I/II Burn Wound Clinical Trial- Initiated Infection Trial DFU DFU Q4 23: Readout of Phase H1: Initiate Phase I/II DFU I/II DFU Trial C

Slide 28: Investment Highlights
Investment Highlights Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Proprietary first-in-class, broad-spectrum anti-infectives against bacteria Multiple clinical indications and formulations in Phase I and II addressing unmet medica

Slide 29: Thank you
Thank you James Graham Managing Director and Chief Executive Officer Recce Pharmaceuticals Ltd ASX:RCE; FSE:R9Q +61 2 9256 2505 james.graham@recce.com.au recce.com.au

Slide 30: Appendix
eve recce.com.au Appendix 29

Slide 31: Empowering Clinicians with a New Class of Antibiotics
Empowering Clinicians with a New Class of Antibiotics The need for new antibiotics has never been greater Physician perspectives on R327 • Initial resistance to use new approved drugs due to antibiotic resistance “We have so few options when patients have difficult pathogens. • “New antibiotics, abl

Slide 32: Recently Approved Antibiotics – Benchmark for Pricing
Recently Approved Antibiotics – Benchmark for Pricing Anticipated Pricing Benchmarks1 USD $25,000 – $30,000 • Though Xigris (activated protein C) was pulled from the market in 2011, its pricing represents a potential premium benchmark for a novel sepsis agent • Fetroja, a recently approved agent for

Slide 33: Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase
Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase Case studies: Other antibiotic companies Price (US$) Volume (m) • Positive top line results from a global, pivotal Oct 2015: Ann. mixed results Phase III clinical trial of solithromycin oral $2 50.00 from 2nd

Slide 34: Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase
Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase Case studies: Other antibiotic companies Price (US$) Volume (m) • In December 2016, Achaogen announces $3 0.00 60 .0 positive results in Phase III cUTI and CRE clinical trials of Plazomicin. $2 5.00 50 .0 • E

Slide 35: Large strategics are also paying attention
Large strategics are also paying attention Case studies: Partnering antibiotic assets creates value GSK and Spero Therapeutics announce exclusive licence US$66 million upfront and Up to US$525 million in potential agreement for late-stage antibiotic that may treat complicated UTIs milestones plus ro

Slide 36: Many recent deals within the anti-infectives space
Many recent deals within the anti-infectives space have seen larger companies with an entrenched presence acquiring smaller Biotech's Key Recent Deals in Infectious Disease Companies Involved Deal Details Total Value Key Takeaways • Amplyx was developing therapies for patients with • Deal Date: Apri
Source: Internet Archive copy of recce.com.au
More decks from Recce Pharmaceuticals Ltd.
Shareholder Meeting (November 2026)19 slides · Nov 6, 2026
Investor Presentation (November 2026)45 slides · November 2026
Investor Presentation (October 2026)42 slides · October 2026
Shareholder Meeting (September 2026)10 slides · Sep 2, 2026
Investor Presentation (September 2026)42 slides · September 2026
Investor Presentation (August 2026)40 slides · August 2026